Physician profile
Peter J Bessas
NPI 1992756498
$3,603.92
in general payments reported to CMS, 2019-2025
19 companies · $1,114 in 2025
The $1,114 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.10 · 2020: $196 · 2021: $668 · 2022: $859 · 2023: $631 · 2024: $121 · 2025: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,865.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $1,307.56 | 2019-2023 | Nocdurna, Xyosted, Tlando |
| Astrazeneca Pharmaceuticals LP | $514.82 | 2020-2025 | Airsupra, Farxiga |
| Pfizer INC. | $453.79 | 2021-2025 | |
| Axsome Therapeutics, INC. | $248.76 | 2023-2025 | Auvelity, Sunosi |
| Biohaven Pharmaceutical Holding Company LTD. | $212.83 | 2022 | |
| Novo Nordisk INC | $202.66 | 2020-2025 | Ozempic, Wegovy |
| Supernus Pharmaceuticals, INC. | $93.07 | 2021-2023 | Xyosted, Qelbree, Tlando |
| Halozyme INC | $91.36 | 2023 | |
| Corium, LLC | $86.58 | 2023 | Azstarys |
| Lundbeck LLC | $76.85 | 2021 | |
| Amgen INC. | $56.57 | 2025 | Otezla, Repatha |
| Lilly USA, LLC | $52.81 | 2025 | Zepbound |
| Biohaven Pharmaceuticals, INC. | $41.62 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.68 | 2025 | Caplyta |
| Madrigal Pharmaceuticals | $37.25 | 2025 | Rezdiffra |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $30.77 | 2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $29.00 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Bessas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.